Group 1 - SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days [1][2] - The compliance determination by Nasdaq indicates that the prior bid price deficiency matter is now closed [2] - SciSparc is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [3] Group 2 - The company is led by an experienced team of senior executives and scientists, emphasizing its expertise in cannabinoid pharmaceuticals [3] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [3]

Core Insights - Reunion Neuroscience Inc. announced the publication of Phase 1 study results for RE104, highlighting its favorable safety profile and short duration psychoactive experience [1][3] - The company is currently conducting the RECONNECT Phase 2 trial for RE104 in postpartum depression, with topline results expected in Q3 2025 [1][2] Group 1: Phase 1 Study Findings - The Phase 1 study involved administering a single subcutaneous dose of RE104 ranging from 5mg to 40mg to healthy adult volunteers, with psychoactive effects lasting 3-4 hours for doses above 5mg [2][6] - RE104 demonstrated a favorable safety and tolerability profile, with no serious adverse events reported, and treatment-emergent adverse events were mostly mild to moderate [3][6] - The active metabolite 4-OH-DiPT appeared rapidly in plasma, correlating with clinical assessments of drug effect [3][6] Group 2: Future Trials and Indications - Reunion Neuroscience plans to initiate the REKINDLE Phase 2 trial for adjustment disorder in Q3 2025, following the RECONNECT trial [5][7] - The company is also conducting a clinical lactation study to assess the elimination of RE104 and its metabolites in breastfeeding mothers, with final data expected in the second half of 2025 [4][5] Group 3: Company Overview - Reunion Neuroscience is focused on developing next-generation psychedelic-inspired therapeutic solutions for mental health disorders, having transitioned to a private company in 2023 and completed Series A financing in 2024 [8] - The lead product candidate, RE104, is designed to provide a shorter duration psychedelic experience compared to traditional psychedelics like psilocybin, while maintaining a similar safety profile [6][8]

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated b ...

PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Belite Bio (BLTE) is a clinical stage biopharmaceutical drug development company which focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. The Zacks Consensus Estimate for its current year earnings has been revised 59.1% downward over the last 60 days.3D Systems (DD ...

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH) , a passively managed exchange traded fund launched on 12/20/2011.Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.Sector ETFs are also funds of convenience, offering many ways to gai ...

Core Insights - Wellgistics Health, Inc. (NASDAQ: WGRX) is set to appear live on YouTube on July 22, 2025, at 1:00 PM EST to discuss its recent performance and future strategy [1][2] Group 1: Company Overview - CEO Brian Norton will lead an unfiltered discussion on WGRX's recent momentum, stock performance, and market outlook [2] - The company is recognized for its role in pharmaceutical distribution and healthcare technology [1] Group 2: Event Details - The live session will be hosted on the Floorstocks channel, which focuses on amplifying rising public companies [2][4] - Retail investors will have the opportunity for direct engagement during the session [2] Group 3: Strategic Insights - The discussion will cover WGRX's disruptive strategy in healthcare distribution and direct-to-patient services [5] - WGRX is integrating XRP blockchain payments into healthcare transactions to enhance efficiency and global accessibility [5] - The session will analyze the recent surge in stock activity and market dynamics [5]

Core Insights - Telix Pharmaceuticals reported a significant increase in Q2 2025 revenue, reaching approximately $204 million, a 63% increase year-over-year, and reaffirmed its FY 2025 revenue guidance of $770 million to $800 million [3][6][22]. Financial Performance - Group revenue for Q2 2025 was $204 million, compared to $125 million in Q2 2024, marking a 63% increase. Revenue for Q1 2025 was $186 million, showing a 10% increase quarter-over-quarter [3][6]. - Global Illuccix® revenue was $154 million in Q2 2025, up 25% from $123 million in Q2 2024, and slightly increased by 2% from $151 million in Q1 2025 [3]. - RLS revenue reached $46 million in Q2 2025, with no revenue reported in Q2 2024, and a 39% increase from $33 million in Q1 2025 [3]. Business Highlights - Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., indicating strong market demand despite competitive pricing pressures [4]. - The launch of Gozellix in the U.S. has commenced, with the product assigned a Level II HCPCS code, a key step towards reimbursement [6]. - The ProstACT Global Phase 3 trial achieved a milestone with all 30 patients consented for Part 1, and the trial is expanding into China, Japan, and Canada [7]. Therapeutics Development - TLX591 (Lu-rosopatamab tetraxetan) is progressing in its Phase 3 trial, with dosing completed for patients in two of the three arms [7]. - TLX592 (Ac-PSMA-RADmAb) has submitted an application for a Phase 1 study in Australia [7]. - TLX101 (I-iodofalan) received HREC approval in Australia for an international pivotal trial [7]. - TLX250 (¹⁷⁷Lu-DOTA-girentuximab) is enrolling patients in a Phase 1b/2 clinical trial for clear cell renal cell carcinoma [7]. Regulatory and Corporate Updates - Telix is cooperating with the U.S. SEC regarding a subpoena for documents related to its prostate cancer therapeutic candidates [11][12]. - The company has received country-level approvals for Illuccix in multiple European countries and is launching on a market-by-market basis [13]. - Telix has completed enrollment for the Illuccix China Phase 3 study, aiming for marketing authorization in Q4 2025 [13]. Manufacturing and R&D - Telix announced a GMP manufacturing facility in Yokohama, Japan, enhancing its global manufacturing strategy [14]. - The TMS facility in Brussels South, Belgium, has produced its first GMP commercial radiopharmaceutical doses [14]. - The company expects a 20% to 25% increase in R&D expenditure for FY 2025 compared to FY 2024 [22].

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill.The facilit ...

Sanofi agrees to buy UK vaccine developer Vicebio for as much as $1.6 billion, as it seeks to expand in respiratory treatments https://t.co/02refS9TM7 ...